Thursday, December 8, 2016

Stop censorship

From https://weneedalaw.ca/2016/11/stop-censorship-tour/

While George Orwell’s ‘1984’ was a warning, it has become a ‘how-to’ manual of sorts for cultural Marxists. Telling the truth requires knowing the facts and being free to talk about them openly. 

The STOP CENSORSHIP TOUR will be hosting an event in Ottawa at the Ottawa Reformed Presbyterian Church on Saturday, January 7 and you are invited to learn about how the Government of Ontario is actively hiding abortion statistics in order to frustrate the ongoing work of helping women and advancing pre-born human rights. 

This event is free to attend and will feature John Sikkema, a lawyer with ARPA (Association for Reformed Political Action) Canada and Mike Schouten, Director of WeNeedaLAW.ca. The event will also feature Pat Maloney, a pro-life blogger from Ottawa who has been fighting for access to abortion data in Ontario. There will be a financial appeal to support the ongoing efforts of WeNeedaLAW.ca.

For more information please email Cassy Knegt at info@weneedalaw.ca



Welcome to Liberal Canada

God help Canada.

First off today we have a disgusting CBC segment on This Hour has 22 minutes where the actor begins by taking the Lord's name in vain in a crude manner like someone from the proverbial locker room. I know this is fine with some people but pretty disgusting behaviour that I can't imagine our tax-payer funded broadcaster would ever get away with if the object of their ridicule were Muslims. The actor then proceeds to ridicule and make fun of the fact that new MPP Sam Oosteroff is against abortion. So very funny (apparently). Naturally anyone who is anti-abortion must be made fun of, right?

And the CBC says they are not biased for abortion? I'd like to see the CBC make fun of pro-choice people. Haha.

(If you are so inclined, and I hope you are, I suggest you send in your complaint to the CBC Ombudsman Esther Enkin at ombudsman@cbc.ca)

Then we have the media being totally moronic about insisting that new MPP Sam Oosterhoff answer their questions about same-sex marriage. Oosterhoff kept insisting he had already answered their questions the day before. Not good enough. Oosterhoff actually remained very gracious in his attempts to focus on his first day as an MPP by celebrating with friends and family. But the ignorant media were having none of that. I would not have been as kind as Oosterhoff. I'm pretty sure.

Last but not least, we learn that a teenager doesn't feel "safe" because her teacher said he was against abortion. The un-named teacher said:
“I find abortion to be wrong...but the law is often different from our personal opinions.”
This is where the story gets really scary:
"A little later, the class had a five-minute break, and when it resumed, several students didn’t return, among them a popular young woman who had gone to an administrator to complain that what the teacher said had “triggered” her such that she felt “unsafe” and that, in any case, he had no right to an opinion on the subject of abortion because he was a man."
What happened next was outrageous. The teacher first apologized, but this wasn't enough. He was fired.

The girl feels unsafe? Are you kidding me? Babies in the womb are not safe. The teacher who was fired for believing that slaughtering unborn babies was wrong...was not safe. Now the teacher's family is not safe because their dad lost his job because he believes that abortion is wrong. That's not safe.

Remember Nazi Germany? When Jews were persecuted? When Jews were not safe? When Jewish academics and others were prevented from working?

This is where Canada has got to. Except now it's Christians.

When Justin Trudeau said that pro-life people can't belong in his party, the rot started at the top. And now it's making its way downward.

Wake up people. This will only get worse.

Monday, December 5, 2016

CBC - big abortion's mouthpiece - Part 3

(Part 1)
(Part 2)
"I cannot understand the need for that. There isn't a medical reason we would need that." Dr. Wendy Norman
So let's look at these strict accessibility guidelines for RU-486 (mifepristone), based on the US example, a country ten times the size of Canada.

Is there a "medical reason" for these guidelines or isn't there?

The CBC has interviewed Dr. Norman at least six times, and each time she questions why Canada has chosen to only allow doctors to dispense this drug, and not pharmacists. Dr. Norman calls this behaviour "strange and bizarre", "highly unusual", an "absolutely inexplicable regulation" and "demeaning".

Decide for yourself.

All the information and links below are from the US's Food and Drug Administration's (FDA) Approved Risk Evaluation and Mitigation Strategies (REMS). (All emphasis in red added)

I. GOAL

The goal of the Mifeprex REMS is to mitigate the risk of serious complications associated with Mifeprex by:
a) Requiring healthcare providers who prescribe Mifeprex to be certified in the Mifeprex REMS Program.
b) Ensuring that Mifeprex is only dispensed in certain healthcare settings by or under the supervision of a certified prescriber.
c) Informing patients about the risk of serious complications associated with Mifeprex 

II. REMS ELEMENTS

A. Elements to Assure Safe Use

1. Healthcare providers who prescribe Mifeprex must be specially certified.
  a. To become specially certified to prescribe Mifeprex, healthcare providers must:
  i. Review the Prescribing Information for Mifeprex.
  ii. Complete the Prescriber Agreement Form. By signing the Prescriber agreement Form, prescribers agree that:
    1) They have the following qualifications:
      a) Ability to assess the duration of pregnancy accurately
      b) Ability to diagnose ectopic pregnancies
      c) Ability to provide surgical intervention in cases of incomplete abortion or severe bleeding, or to have made plans to provide such care through others, and ability to assure patient access to medical facilities equipped to provide blood transfusions and resuscitation, if necessary.
    2) They will follow the guidelines for use of Mifeprex (see b.i-v below).
  
b. As a condition of certification, healthcare providers must follow the guidelines for use of Mifeprex described below:

  i. Review the Patient Agreement Form with the patient and fully explain the risks of the Mifeprex treatment regimen. Answer any questions the patient may have prior to receiving Mifeprex.
  ii. Sign the Patient Agreement Form and obtain the Patient’s signature on the Form
  iii. Provide the patient with a copy of the Patient Agreement Form and Medication Guide.
  iv. Place the signed Patient Agreement Form in the patient's medical record.
  v. Record the serial number from each package of Mifeprex in each patient’s record.
  vi. Report any deaths to Danco Laboratories, identifying the patient by a nonidentifiable reference and the serial number from each package of Mifeprex.

c. Danco Laboratories must:

  i. Ensure that healthcare providers who prescribe Mifeprex are specially certified in accordance with the requirements described above and de-certify healthcare providers who do not maintain compliance with certification requirements 
  ii. Provide the Prescribing Information and Prescriber Agreement Form to healthcare providers who inquire about how to become certified. 

The following materials are part of the REMS and are appended:
• Prescriber Agreement Form
• Patient Agreement Form

2. Mifeprex must be dispensed to patients only in certain healthcare settings, specifically clinics, medical offices, and hospitals, by or under the supervision of a certified prescriber.

  a. Danco Laboratories must:

    i. Ensure that Mifeprex is available to be dispensed to patients only in clinics, medical offices and hospitals by or under the supervision of a certified prescriber.
    ii. Ensure that Mifeprex is not distributed to or dispensed through retail pharmacies or other settings not described above.

3. Mifeprex must be dispensed to patients with evidence or other documentation of safe use conditions.
  a. The patient must sign a Patient Agreement Form indicating that she has:
    i. Received, read and been provided a copy of the Patient Agreement Form.
    ii. Received counseling from the prescriber regarding the risk of serious complications associated with Mifeprex.

B. Implementation System

1. Danco Laboratories must ensure that Mifeprex is only distributed to clinics, medical offices and hospitals by or under the supervision of a certified prescriber by:
  a. Ensuring that distributors who distribute Mifeprex comply with the program requirements for distributors. The distributors must:
    i. Put processes and procedures in place to:
      a. Complete the healthcare provider certification process upon receipt of the Prescriber Agreement form.
      b. Notify healthcare providers when they have been certified by the Mifeprex REMS Program.
      c. Ship Mifeprex only to clinics, medical offices, and hospitals identified by certified prescribers in the signed Prescriber Agreement Form.
      d. Not ship Mifeprex to prescribers who become de-certified from the Mifeprex Program.
      e. Provide the Prescribing Information and Prescriber Agreement Form to healthcare providers who (1) attempt to order Mifeprex and are not yet certified, or (2) inquire about how to become certified.
    ii. Put processes and procedures in place to maintain a distribution system that is secure, confidential and follows all processes and procedures, including those for storage, handling, shipping, tracking package serial numbers, proof of delivery and controlled returns of Mifeprex.
    iii. Train all relevant staff on the Mifeprex REMS Program requirements.
    iv. Comply with audits by Danco Laboratories, FDA or a third party acting on behalf of Danco Laboratories or FDA to ensure that all processes and procedures are in place and are being followed for the Mifeprex REMS Program. In addition, distributors must maintain appropriate documentation and make it available for audits.
    b. Ensuring that distributors maintain secure and confidential distribution records of all shipments of Mifeprex.

  2. Danco Laboratories must monitor distribution data to ensure compliance with the REMS Program.
  3. Danco Laboratories must audit new distributors within 90 calendar days after the distributor is authorized to ensure that all processes and procedures are in place and functioning to support the requirements of the Mifeprex REMS Program. Danco Laboratories will take steps to address distributor compliance if noncompliance is identified.
  4. Danco Laboratories must take reasonable steps to improve implementation of and compliance with the requirements of the Mifeprex REMS Program based on monitoring and assessment of the Mifeprex REMS Program.
  5. Danco Laboratories must report to FDA any death associated with Mifeprex whether or not considered drug-related, as soon as possible but no later than 15 calendar days from the initial receipt of the information by the applicant. This requirement does not affect the applicant's other reporting and follow-up requirements under FDA regulations.

C. Timetable for Submission of Assessments
Danco Laboratories must submit REMS assessments to FDA one year from the date of the initial approval of the REMS (06/08/2011) and every three years thereafter. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. Danco Laboratories must submit each assessment so that it will be received by the FDA on or before the due date.
_________________________________________________________________________

What do participants need to know?

Healthcare Providers who prescribe and dispense Mifeprex must To be able to prescribe:
  • Review the drug’s prescribing information.
  • Complete and submit the Prescriber Agreement Form.
Healthcare Providers who prescribe and dispense Mifeprex  must Before dispensing
  • Review the Patient Agreement Form with the patient and fully explain the risks of the Mifeprex treatment regimen.
  • Provide the patient with the Medication Guide.
  • Complete the Patient Agreement Form with the patient. Provide a completed copy of the form to the patient and retain a completed copy in the patient’s record.
  • Complete the Patient Agreement Form with the patient. Provide a completed copy of the form to the patient and retain a completed copy in the patient’s record.
Patients who are prescribed Mifeprex Before receiving
  • Review the Patient Agreement Form.
  • Complete the Patient Agreement Form with the prescriber.
  • Receive counseling from the prescriber on the risks associated with Mifeprex.
Distributors that distribute Mifeprex must To be able to distribute
  • Establish processes and procedures to ensure that the drug is distributed only to clinics, medical offices, and hospitals identified by certified healthcare providers.
  • Establish processes and procedures to maintain a distribution system that is secure and confidential.
  • Establish processes and procedures to maintain a system for proper storage, handling, shipping, tracking package serial numbers, proof of delivery and controlled returns of Mifeprex.
  • Train all relevant staff involved in distribution of Mifeprex on the REMS Program requirements.
Distributors that distribute Mifeprex must At all times
  • Maintain confidential distribution records of all shipments of Mifeprex.
  • Cooperate with audits carried out by the application holder to ensure that all processes and procedures are in place and are being followed.
Patient must fill out this form (1 page):

Doctor must fill out this form (2 page):

Medication guide for patient (4 pages) 

FDA warning:
"You should not buy Mifeprex over the Internet because you will bypass important safeguards designed to protect your health (and the health of others). 
Mifeprex has special safety restrictions on how it is distributed to the public. Also, drugs purchased from foreign Internet sources are not the FDA-approved versions of the drugs, and they are not subject to FDA-regulated manufacturing controls or FDA inspection of manufacturing facilities
To learn more about buying drugs safely, please see Buying Prescription Medicines Online: A Consumer Safety Guide"
Mifepristone U.S. Postmarketing Adverse Events Summary through 04/30/2011 (including deaths, hospitalizations, blood transfusions, ectopic pregnancies and infections):

Sunday, December 4, 2016

CBC - big abortion's mouthpiece - Part 2

CBC can't see how biased they are. I have detailed their bias here in part 1 as it relates to the abortion pill RU-486.

The Ombudsman thinks that I am concerned about Health Canada's position on the drug:
"the CBC covered the introduction of Mifepristone into Canada over a period of time and on multiple platforms and programmes. Many of those did adequately represent the position of Health Canada and its reasons for the regime required for use of the drug in Canada."
My complaint made no mention of Health Canada. Yet the Ombudsman talks about their story being balanced as regards to Health Canada, which I never mentioned in my complaint. Rather my complaint was about the fact that the CBC chose only ever to ask an abortion doctor her opinion as to why the drug was being dispensed this way [by doctors and not pharmacists]. The CBC did not ask that question of a pro-life doctor. Why not? If the CBC had asked a pro-life doctor, I'm pretty sure they would have received quite a different answer.

The Ombudsman said my complaint was not about the safety about the drug but rather accessibility of the drug. My point was that you cannot properly discuss the accessibility of the drug, if you don't also discuss its safety. That is because accessibility is directly related to the fact that the drug is so dangerous. What part of this does the CBC not understand?

The person the CBC chose to interview on accessibility is an abortion doctor who naturally has a vested interest in abortions. And RU-486 is abortion. The CBC did not interview a pro-life doctor on accessibility, and I can guarantee if they had, that doctor would have brought up the important issue of the dangers of the drug. But the CBC did not do this. And as I already pointed out in the first installment on this, the CBC didn't do this over time either. Nearly all their reporting on this drug has been biased for abortion as they only ever interview people from the abortion industry.

Why doesn't the CBC interview someone not from the abortion industry and let the reader make up their own mind?

Let's look at another controversial issue which is currently being debated and a recent decision made this week by the government: pipelines. CBC interviews people on both sides of that debate, those who oppose the proposed pipelines and those who support them. The CBC would never think of interviewing only those people who support pipelines or only those who oppose pipelines when covering the government's decisions regarding the Kinder Morgan and the Northern Gateway pipelines. Like pipelines, RU486 is controversial. Both involve government's decision whether to approve or not and both involve regulations if/when they are approved,  Those who oppose pipelines will be more likely to focus on the negative things that result from allowing the pipelines to be built; those who support pipelines will be more likely to downplay the negative aspects of the pipelines and highlight the positive. Surely the CBC can see that if they interviewed only people who held the former position, or only those who held the latter, they would be biased. No different with RU-486: If someone supports RU-486 in the first place, their views on accessibility will be coloured by that, as will someone who opposes it.

The Ombudsman also seems to issue with my calling Dr. Norman an "abortion doctor":
"You describe her as an “abortion doctor”. As Ms. Hiscox mentioned in her introduction her qualifications are extensive in the field of public health as well as family planning. According to the Canadian Institutes of Health Research (the federal funding agency for health research) website, she is also the Applied Public Health Chair of that organization."
That's because:
"Dr. Norman has been a family physician since 1985 and has practiced exclusively in the area of abortion since 1997". (emphasis added)
More later...

Thursday, December 1, 2016

Social conservatives of Canada - buy a membership for CPC leadership

We social conservatives never give up. We keep on trucking. We never stop defending the unborn. We never stop defending parents' right to decide on the sex-ed curriculum for their children.

Next May 2017 we have the opportunity to vote for the next leader of the Conservative Party of Canada. It's a crowded contingency of leadership hopefuls. But there are really only two candidates who will support what we believe in, that is, true social conservative values: Pierre Lemieux and Brad Trost. Even though Andrew Scheer is pro-life he won't have reopen abortion debate.

I always laugh when I hear Justin Trudeau talk about Canadian values. The values he talks about are not my values--never have been and never will be.

This is really really important that we make our votes count in this leadership race. I did today when my husband and I bought a membership and supported Pierre Limieux. Here is Brad Trost's donation page.

All of the votes for a candidate who holds our values will count in the party, regardless as to who wins. Our membership tells the party that we matter. All social conservatives need to buy a membership for one of these candidates. Every single one of us needs to do this. We can't just say we support social conservative candidates, we need to put our hands into our wallets and pull out $15 and buy a membership.

This is our chance to stand up for our values, not Justin Trudeau's values